Search Results - "Kamgar, Mandana"

Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review by Mody, Juhi, Kamgar, Mandana

“…Abstract Introduction: Mutation in Kristin ras sarcoma virus (KRAS) oncogene is the main driver in pancreatic ductal adenocarcinoma (PDAC) and is present in…”
Get full text

Total Neoadjuvant Therapy for Operable Pancreatic Cancer by Kim, Rebecca Y., Christians, Kathleen K., Aldakkak, Mohammed, Clarke, Callisia N., George, Ben, Kamgar, Mandana, Khan, Abdul H., Kulkarni, Naveen, Hall, William A., Erickson, Beth A., Evans, Douglas B., Tsai, Susan

“…Background Overall survival (OS) for operable pancreatic cancer (PC) is optimized when 4–6 months of nonsurgical therapy is combined with pancreatectomy…”
Get full text

Third national Surveillance of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007) in Iran: methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia by Esteghamati, Alireza, Meysamie, Alipasha, Khalilzadeh, Omid, Rashidi, Armin, Haghazali, Mehrdad, Asgari, Fereshteh, Kamgar, Mandana, Gouya, Mohammad Mehdi, Abbasi, Mehrshad

“…The burden of non-communicable diseases is rising globally. This trend seems to be faster in developing countries of the Middle East. In this study, we…”
Get full text

Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology by Hall, William A., Kamgar, Mandana, Erickson, Beth A., Ponce, Sara Beltrán, Tsai, Susan, Nevalainen, Marja T., Christians, Kathleen K., George, Ben, Dua, Kulwinder S., Khan, Abdul H., Evans, Douglas B., Azmi, Asfar S.

“…Panc reatic ductal adenocarcinoma (PDAC) is a devastating malignancy. There have been few advances that have substantially improved overall survival in the…”
Get full text

Comprehensive genomic profiling: Does timing matter? by Thapa, Bicky, Ahmed, Gulrayz, Szabo, Aniko, Kamgar, Mandana, Kilari, Deepak, Mehdi, Maahum, Menon, Smitha, Daniel, Sherin, Thompson, Jonathan, Thomas, James, George, Ben

“…There is variability in utilization of Comprehensive Genomic Profiling (CGP) in most of the metastatic solid tumors (MST). We evaluated the CGP utilization…”
Get full text

A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer by Bodeker, Kellie L., Smith, Brian J., Berg, Daniel J., Chandrasekharan, Chandrikha, Sharif, Saima, Fei, Naomi, Vollstedt, Sandy, Brown, Heather, Chandler, Meghan, Lorack, Amanda, McMichael, Stacy, Wulfekuhle, Jared, Wagner, Brett A., Buettner, Garry R., Allen, Bryan G., Caster, Joseph M., Dion, Barbara, Kamgar, Mandana, Buatti, John M., Cullen, Joseph J.

“…Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) have poor 5-year survival. Pharmacological ascorbate (P-AscH-, high dose, intravenous, vitamin…”
Get full text

Prevalence and predictors of peripheral neuropathy after breast cancer treatment by Kamgar, Mandana, Greenwald, Mark K., Assad, Hadeel, Hastert, Theresa A., McLaughlin, Eric M., Reding, Kerryn W, Paskett, Electra D., Bea, Jennifer W., Shadyab, Aladdin H., Neuhouser, Marian L., Nassir, Rami, Crane, Tracy E., Sreeram, Kalyan, Simon, Michael S.

“…Background Many of the 3.8 million breast cancer survivors in the United States experience long‐term side effects of cancer therapy including peripheral…”
Get full text

Phase II clinical trial of nab‐paclitaxel plus cisplatin plus gemcitabine (NABPLAGEM) in patients with untreated advanced pancreatic cancer by Jameson, Gayle S., Hosein, Peter J., Pierce, Erin, Kamgar, Mandana, Gordon, Michael S., Snyder, Courtney, Roe, Denise J., Wertheim, Betsy C., Davey, Marina, Barrett, Michael T., Von Hoff, Daniel D., Borazanci, Erkut

“…Background A previous phase IB/II study of nab‐paclitaxel + cisplatin + gemcitabine (NABPLAGEM) in 25 patients with previously untreated metastatic pancreatic…”
Get full text

The impact of pre-transplant dialysis on simultaneous pancreas-kidney versus living donor kidney transplant outcomes by Wiseman, Alexander C, Huang, Edmund, Kamgar, Mandana, Bunnapradist, Suphamai

“…Pre-transplant dialysis is known to affect kidney graft survival. Here, we report the impact of pre-transplant dialysis on patient and graft survival of type 1…”
Get full text

Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy by Ortiz de Choudens, Saryleine, Visotcky, Alexis, Banerjee, Anjishnu, Aldakkak, Mohammed, Tsai, Susan, Evans, Douglas B., Christians, Kathleen K., Clarke, Callisia N., George, Ben, Shreenivas, Aditya, Kamgar, Mandana, Chakrabarti, Sakti, Dua, Kulwinder S., Khan, Abdul Haq, Madhavan, Srivats, Erickson, Beth A., Hall, William A.

“…Purpose/Objectives Most patients with pancreatic adenocarcinoma (PDAC) will present with distant metastatic disease at diagnosis. We sought to identify…”
Get full text

Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy by Khan, Husain Yar, Kamgar, Mandana, Aboukameel, Amro, Bannoura, Sahar, Chung, Brian Y., Li, Yiwei, Hallak, Mohammed Najeeb Al, Philip, Philip A., Tsai, Susan, Luther, Sanjeev, Hall, William A., Azmi, Asfar S.

“…Local tumor progression is a cause of significant morbidity and mortality in patients with pancreatic ductal adenocarcinoma (PDAC) with surgically unresectable…”
Get full text

Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm by Chakrabarti, Sakti, Kamgar, Mandana, Mahipal, Amit

“…Biliary tract cancers (BTCs) are a heterogeneous group of adenocarcinomas that originate from the epithelial lining of the biliary tree. BTCs are characterized…”
Get full text

Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities by Chakrabarti, Sakti, Kamgar, Mandana, Mahipal, Amit

“…Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by nonspecific presenting symptoms, lack of a screening test, rapidly…”
Get full text

Goals of Treatment Sequencing for Localized Pancreatic Cancer by Evans, Douglas B., Kamgar, Mandana, Tsai, Susan

“…Background: The aim of this study was to evaluate the prognostic significance of clinicalpathologic variables in melanoma of the vulva. Methods: From 1979…”
Get full text

Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma by Kamgar, Mandana, Chakrabarti, Sakti, Shreenivas, Aditya, George, Ben

“…Pancreatic ductal adenocarcinoma is characterized by early systemic dissemination, a complex tumor microenvironment, as well as significant intratumoral and…”
Get full text

Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm by Chakrabarti, Sakti, Kamgar, Mandana, Mahipal, Amit

“…Biliary tract cancers (BTCs) are a heterogeneous group of adenocarcinomas that originate from the epithelial lining of the biliary tree. BTCs are characterized…”
Get full text

Prognostic effect of RAS/BRAF mutations in patients (pts) with metastatic colorectal cancer (mCRC) by Abid, Haisam, Szabo, Aniko, Taylor, Bradley W., Shreenivas, Aditya V., Chakrabarti, Sakti, Kamgar, Mandana, Thomas, James P., George, Ben

“…Abstract only 191 Background: Somatic alterations in KRAS and BRAF have prognostic as well as predictive impact in pts with mCRC; however, the differential…”
Get full text

The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities by Tesfaye, Anteneh A., Kamgar, Mandana, Azmi, Asfar, Philip, Philip A.

“…Introduction: Pancreatic ductal adenocarcinoma (PDAC) is projected to be the second leading cause of cancer related mortality in the United States in 2030,…”
Get full text

A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma by Saif, Areeba, Verbus, Emily, Erickson, Beth, Kamgar, Mandana, Tsai, Susan, Evans, Douglas, Hernandez, Jonathan M., Hall, William A.

Get full text

Clinical course and outcome of patients developing capecitabine-induced non-neutropenic enterocolitis (NNEC): An institutional analysis by Parish, Marie, Cox, Ronald, Thapa, Bicky, McKenna, Edward, Oxencis, Carolyn, Shreenivas, Aditya V., Kamgar, Mandana, George, Ben, Thomas, James P., Chakrabarti, Sakti

“…Abstract only 656 Background: Non-neutropenic enterocolitis (NNEC), a potentially fatal toxicity of capecitabine (CAPE), is under-reported in the literature…”
Get full text